MicroRNA-493 is a prognostic factor in triple-negative breast cancer

Cancer Science
Ling YaoZhiming Shao

Abstract

Breast cancer is one of the most common malignant diseases in women. Triple-negative breast cancer (TNBC) shows higher aggressiveness and recurrence rates than other subtypes, and there are no effective targets or tailored treatments for TNBC patients. Thus, finding effective prognostic markers for TNBC could help clinicians in their ability to care for their patients. We used tissue microarrays (TMAs) to detect microRNA-493 (miR-493) expression in breast cancer samples. A miRCURY LNA detection probe specific for miR-493 was used in in situ hybridization assays. Staining results were reviewed by two independent pathologists and classified as high or low expression of miR-493. Kaplan-Meier survival plots and multivariate Cox analysis were carried out to clarify the relationship between miR-493 and survival. In the Kaplan-Meier analysis, patients with high miR-493 expression had better disease-free survival than patients with low miR-493 expression. After adjusting for common clinicopathological factors in breast cancer, the expression level of miR-493 was still a significant prognostic factor in breast cancer. Further subtype analysis revealed that miR-493 expression levels were only significantly prognostic in TNBC patients. Th...Continue Reading

References

Nov 10, 2007·The Journal of Biological Chemistry·Lisa B FrankelAnders H Lund
Apr 3, 2009·Chromosoma·Rachael A Nimmo, Frank J Slack
Jul 4, 2009·The Journal of Biological Chemistry·Irene K Guttilla, Bruce A White
Dec 10, 2009·Cancer Research·Mohit Sachdeva, Yin-Yuan Mo
Apr 8, 2010·The Journal of Biological Chemistry·William KongJin Q Cheng
Oct 5, 2011·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Aug 1, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yong LiuQing-Song Xi
Aug 30, 2013·JAMA Surgery·Cindy B Matsen, Leigh A Neumayer
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Nov 1, 2013·Recent Patents on Anti-cancer Drug Discovery·Jo-Anne de la MareAdrienne L Edkins
Jun 10, 2014·The Journal of Clinical Investigation·Chi-Hong ChaoChun-Ju Chang
Aug 12, 2014·Cancer Letters·Melina-Theoni GyparakiAthanasios G Papavassiliou
Apr 11, 2015·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Karolina Zaleska
Apr 17, 2015·The Oncologist·Conleth G Murphy, Maura N Dickler
Oct 3, 2015·CA: a Cancer Journal for Clinicians·Elizabeth M WardTed Gansler
Oct 30, 2015·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Jan 28, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yi-Rong LiuZhi-Ming Shao
Aug 9, 2016·Journal of Thoracic Disease·Zhi-Gang CaoZhi-Min Shao
Nov 3, 2016·Breast Cancer Research and Treatment·András LánczkyBalázs Győrffy
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 14, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·William J GradisharRashmi Kumar
May 6, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Aili CuiYinghua An

❮ Previous
Next ❯

Citations

Jan 7, 2020·Oncotarget·Eleni ZografosMeletios-Athanasios Dimopoulos
Oct 20, 2018·MicroRNA·Emmanuel N. KontomanolisNikolaos J. Kambas
Sep 11, 2021·Current Cancer Drug Targets·Acharya BalkrishnaVedpriya Arya

❮ Previous
Next ❯

Software Mentioned

SPSS
miRpower
METABRIC

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.